Phase II trial of Cetuximab in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

Alessandro D. Santin, MD[1], **Michael W. Sill, PhD**[2], **D. Scott McMeekin, MD**[3], **Mario M. Leitao Jr., MD**[4], **Jubilee Brown, MD**[5], **Gregory P. Sutton, MD**[6], **Linda Van Le, MD**[7], **Patricia Griffin, MD**[8], and **Cecelia H. Boardman, MD**[9]

[1]Yale University School of Medicine; New Haven, CT

[2]Gynecologic Oncology Group Statistical & Data Center; Roswell Park Cancer Institute; Buffalo, NY; Dept. of Biostatistics, SUNY at Buffalo, Buffalo, NY

[3]University of Oklahoma, Oklahoma City, OK

[4]Memorial Sloan-Kettering Cancer Center, New York, NY

[5]MD Anderson Cancer Center, Houston, TX

[6]Saint Vincent Hospital; Indianapolis, IN

[7]University of North Carolina, Chapel Hill; Chapel Hill, NC

[8]Upstate Carolina CCOP, Spartanburg, SC

[9]Virginia Commonwealth University Health System, Massey Cancer Center, Richmond, VA

Abstract

Purpose—The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of the anti-EGFR antibody cetuximab, in persistent or recurrent carcinoma of the cervix.

Patients and Methods—Eligible patients had cervical cancer, measurable disease, and GOG performance status ≤2. Treatment consisted of cetuximab 400 mg/m^2 initial dose followed by 250 mg/m^2 weekly until disease progression or prohibitive toxicity. The primary endpoints were progression-free survival (PFS) at 6 months and response. The study used a 2-stage group sequential design.

Results—Thirty-eight patients were entered with 3 exclusions, leaving 35 evaluable for analysis. Thirty-one patients (88.6%) received prior radiation as well as either 1 (n = 25, 71.4%) or 2 (n = 10) prior cytotoxic regimens. Twenty-four patients (68.6%) had a squamous cell carcinoma. Grade 3 adverse events possibly related to cetuximab included dermatologic (n = 5), GI (n = 4), anemia

Corresponding Author: Alessandro D. Santin MD Yale University School of Medicine Department of Obstetrics, Gynecology & Reproductive Sciences Room 305 LSOG, 333 Cedar Street P.O. Box 208063 New Haven, CT 06520-8063 Phone: 203-737-4450 FAX: 203-737-4339 alessandro.santin@yale.edu.

CONFLICT OF INTEREST Dr. Cecelia H. Boardman is on the Speaker's Bureau for Glaso-Smith-Kline and Merck. All other co-authors have no conflict of interest to declare.

(n = 2), constitutional (n = 3), infection (n = 2), vascular (n = 2), pain (n = 2), and pulmonary, neurological, vomiting and metabolic (n = 1 each). No clinical responses were detected. Five patients (14.3%; two-sided 90% CI, 5.8% to 30%) survived without progression for at least 6 months. The median PFS and overall survival (OS) times were 1.97 and 6.7 months, respectively. In this study, all patients with PFS at 6 months harbored tumors with squamous cell histology.

Conclusion—Cetuximab is well tolerated but has limited activity in this population. Cetuximab activity may be limited to patients with squamous cell histology.

Keywords

Cervical neoplasms; cetuximab; EGFR; immunotherapy

INTRODUCTION

Cervical cancer remains the second leading cause of cancer death among women worldwide and remains an important health problem for women especially in underserved and minority groups in the Unites States [1]. Although cervical cancer can be cured by radical surgery or radiotherapy with equal effectiveness, pelvic chemo-radiation represents the standard therapy for the treatment of locally advanced disease [2]. Despite technological advances, however, up to 35% of patients overall will develop persistent/recurrent/metastatic disease. Platinum-based chemotherapy represents the gold standard therapy for the treatment of cervical cancer patients who have not responded to primary therapy or have recurrent disease no longer amenable to control with surgery and/or radiation therapy. Unfortunately, most responses to chemotherapy are partial and of short duration, and the most effective treatment of patients with progressive disease on platinum-based chemotherapy has yet to be defined.

The epidermal growth factor receptor (EGFR; HER1/erbB-1) has recently been identified as a target for cancer therapy in multiple human tumors [3–8]. On endogenous ligand binding, EGFR activation occurs, with receptor homo- or heterodimerization and autophosphorylation of the intracellular tyrosine kinase domain [9,10]. Subsequently, a complex network of signal transduction pathways is induced, which plays a key role in regulating cell proliferation, differentiation, motility, invasion, and angiogenesis [9–13]. EGFR is expressed in a variety of human malignancies and its high level of expression has been previously correlated with poor patient prognosis and resistance to treatment in many tumor entities including cervical carcinoma [13–18].

Cetuximab (C225) is a human/murine chimeric monoclonal antibody formed by cloning the heavy and light chains of the murine antibody (M225) and adapting them for expression with the constant regions of the human immunoglobulin kappa light chain and gamma 1 heavy chain [4,6,19]. Preclinical studies have demonstrated that cetuximab binds to the EGFR with high affinity and is able to compete with EGF and TGFα binding, thereby inhibiting subsequent receptor activation and signaling [20,21]. In addition, binding of cetuximab to EGFR induces receptor dimerization, internalization and receptor down regulation [22,23]. These processes may consequently lead to several effects such as cell-cycle arrest via upregulation of cyclin-dependent kinase inhibitor p27^{KIP1}, and potentiation of apoptosis [24,25]. Other effects include inhibition of tumor production of VEGF leading to reduced tumor microvessel density and inhibition of invasion and metastases by inhibiting matrix metalloproteinases [26,27].

Clinical studies of cetuximab either alone or in combination with cytotoxic agents have demonstrated efficacy in patients with chemotherapy-refractory head and neck or colorectal cancer [28–32]. In patients with irinotecan-refractory advanced colorectal cancer, treatment

with cetuximab either as a single agent or in combination with irinotecan resulted in overall remission rates of 10.8% (95% CI, 5.7% to 18.1%) and 22.9% (95% CI, 17.5% to 29.1%), respectively [30–31]. Similar results have been reported for patients with platinum-refractory head and neck cancer or non–small-cell lung cancer with cetuximab in combination with chemotherapy [32].

Cervical cancer patients with metastatic/recurrent disease not amenable to radical local excision or regional radiation and who have progressed on platinum-based chemotherapy have limited therapeutic options. The GOG conducted a phase II trial of single-agent cetuximab in patients with persistent or recurrent squamous or non-squamous cervical carcinoma. The primary endpoints of this study were the frequency of patients with tumor responses or who survived progression-free for at least 6 months (PFS at 6 months). The secondary objectives were to estimate the distribution of overall survival (OS), the distribution of PFS, the duration of objective response, and the frequency and severity of adverse events.

MATERIALS AND METHODS

Eligibility

Eligibility criteria included patients with persistent or recurrent squamous and non-squamous cell carcinoma of the cervix that was measurable by Response Evaluation Criteria in Solid Tumors (RECIST); one or two prior cytotoxic regimens, not including prior cisplatin-based chemotherapy concomitantly administered with primary pelvic radiation; GOG performance status (PS) of 0 or 1, with PS level 2 allowed in patients having received only one prior cytotoxic regimen; and adequate hematologic (absolute neutrophil count ≥1,500/μL and platelets ≥100,000/μL), renal (serum creatinine ≤1.5× the institutional upper limit of normal [ULN]); hepatic (serum bilirubin ≤1.5× ULN, and both AST and alkaline phosphatase ≤2.5× ULN) laboratory values. Histologic documentation of the original primary tumor was required with a pathology report.

Patients with other malignancies evident within 5 years, prior non-cytotoxic therapy with tyrosine kinase inhibitors or another antibody that targets the EGFR pathway for management of recurrent or persistent cervical cancer, infection requiring antibiotics, active bleeding or central nervous system (CNS) disease (craniospinal metastases, uncontrolled seizure disorder) were ineligible. Patients were also excluded for significant cardiovascular disease (uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure, or uncontrolled arrhythmias within 6 months of registration) pregnancy or nursing, or major surgical procedures within 30 days or anticipated while on study. The study received local institutional review board approval at participating institutions and all patients provided authorization permitting the release of personal health information and gave informed consent according to institutional and federal guidelines before enrollment.

Treatment

Patients were treated with an initial dose of 400 mg/m^2 of cetuximab followed by 250 mg/m^2 weekly until disease progression or prohibitive toxicity. Each 28 day period was considered 1 cycle. Toxicity was monitored with history, physical examination, and laboratory assessment before each treatment cycle, with adverse events defined and graded according to National Cancer Institute Common Terminology Criteria version 3.0. and 4.0 Cetuximab was to be held for grade 3 non-hematologic toxicity for a maximum of 4 weeks to allow resolution to grade 2 or less. Treatment was discontinued for any grade 4 non hematologic toxicity or the 4th occurrence of a grade 3 acneiform rash.

Evaluations

Activity of cetuximab was assessed according to RECIST (1.0 version), either by clinical evaluation, computed tomography or magnetic resonance imaging at baseline, and before every other cycle for the measurement of target lesions, the classification of clinical response, and the determination of disease progression. Therapy was discontinued if there was disease progression, unacceptable toxicity, receipt of other anticancer therapy, or voluntary withdrawal.

Statistical Design

The primary endpoints to evaluate the activity of cetuximab were the frequency of patients who had either a tumor response or survived progression-free for 6 months (PFS at 6 months). A 2-stage group sequential design was employed with a targeted sample size for the first stage accrual of 19 patients but was allowed to deviate for administrative purposes [33]. If 20 patients were accrued, the critical values to proceed to the second stage for the number of patients with responses or PFS at 6 months were 2. The cumulative targeted accrual for the second stage was 34 but was allowed to deviate. If 35 patients were accrued, the critical values for the number of patients with responses or PFS at 6 months were 7 before cetuximab was deemed worthy of further investigation in a phase III trial. The null hypothesis was determined from an examination of a historical control of a similar population treated within GOG studies. Values of uninteresting probabilities of response and PFS at 6 months were determined to be 10% or less. The design had a level of significance of 10% with approximately 90% power to detect an increase in the probability of either outcome by 20%.

The distribution of PFS and OS for patients on this study was described using Kaplan-Meier plots and median estimates. Prognostic factors were evaluated with Cox proportional hazards models using end points for PFS and OS [34]. The factors assessed included performance status of 0 or worse along with squamous versus non-squamous histology. Formal inference could not be done on race since there were only 5 African-Americans on study. These analyses are considered exploratory.

RESULTS

Patient characteristics

From June 2007 through July 2009, 38 patients were enrolled, of whom 3 were excluded (1 for inappropriate prior therapy, 1 because required tests were not performed, and 1 for no documentation of treatment with cetuximab). Thus, the study sample consisted of 35 patients; 26 patients (74.3%) were Caucasian, 5 patients (14.3%) were African-American, 2 patients (5.7%) were Asian and 2 (5.7%) were Hispanic. Patient characteristics of the study group are listed in Table 1.

A total of 103 cycles of cetuximab were administered, with 18 patients receiving 2 cycles of treatment (51.4%). As of July 2010, all patients have discontinued therapy, 31 patients were taken off of study for disease progression, 3 discontinued therapy for toxicity as permitted by protocol, and one was taken off study protocol for other reasons (i.e., physician decision). Twenty-six patients died of disease progression. Seven patients (20%) are alive; one patient died from treatment and disease and another died from neither treatment nor disease.

Activity of cetuximab

The first stage of the study acquired 20 eligible and evaluable patients. None of these patients had tumor responses but 4 were PFS at 6 months, which was sufficient to open the study to a second stage. The activity of cetuximab was analyzed in a cumulative number of

35 patients. No clinical responses were detected (Table 2). Five patients (14.3%; two-sided 90% CI, 5.8% to 30%) were PFS at 6 months. The median PFS and OS times were 1.97 and 6.7 months, respectively. The graph of the Kaplan-Meier estimates of PFS and OS for the sample is shown in Figure 1. All 5 patients with PFS at 6 months harbored tumors with squamous cell histology, which comprised 69% of the sample. In an exploratory subgroup analysis of these patients, the point estimates for the probability of being progression-free at 6 months was higher among the squamous patients than the whole sample (21% versus 14%, Figure 2). The 95% CI for the odds ratio was 0.59 to infinity.

Adverse Events

As shown in Table 3, safety of cetuximab in all 35 patients was analyzed descriptively; events listed had been reported as at least possibly related to study drug. There were no grade 4 events. One patient was listed by the GOG Data Safety and Monitoring Board as having died from both treatment and disease (bowel perforation) but the institution did not agree. Grade 3 adverse events at least possibly related to cetuximab included dermatologic events (n = 5), GI (n = 4), anemia (n = 2), constitutional symptoms (n = 3), infection (n = 2), vascular events (n = 2), pain (n = 2), and pulmonary, neurological, vomiting and metabolic events (n = 1 each).

Exploratory Analysis of Patient Characteristics and PFS and OS During Treatment With Cetuximab

Results of the exploratory analyses are reported in Table 4. Performance status may be a prognostic factor associated with OS and possibly PFS. The low number of African Americans included in our study (i.e., a total of 5 patients) prevented the determination of the confidence interval between races. The approximate 95% confidence interval for squamous cell type versus all other cell types ranged from 0.33 – 1.52 for PFS and from 0.33 – 1,57 for OS, respectively, indicating uncertainty of the activity of single agent cetuximab within this subgroup.

DISCUSSION

The management of cervical cancer no longer amenable to control with surgery or radiation therapy has only minimally improved with the advent of modern chemotherapy. The median survival rate for these patients when treated with current systemic cisplatin combination regimens is only 9 to 10 months [35,36]. Thus, the development of innovative, effective therapies against advanced/recurrent/metastatic cervical cancer refractory to standard salvage treatment remains a high priority.

One class of agents with potential activity in this group of patients is represented by cetuximab, a human/murine chimeric monoclonal antibody targeting the epidermal growth factor receptor. Phase I/II studies of cetuximab in locoregionally advanced squamous-cell cancer of the head and neck (SCCHN) showed promising activity in combination with radiotherapy [37,38]. Importantly, in patients with metastatic and recurrent SCCHN who have not responded to platinum-based therapy, cetuximab as a single agent or in combination with chemotherapy has been shown to induce responses. In the study by Baselga et al., patients with metastatic and recurrent SCCHN who had progressed following a platinum-containing regimen were re-challenged with the same regimen with the addition of cetuximab [39]. In 96 evaluable patients, the proportion responding was 14.6% and 39.6% had stable disease. Vermorken et al. evaluated cetuximab monotherapy in 103 patients with metastatic and recurrent SCCHN who had progressed following a platinum-containing regimen [40]. Treatment with cetuximab produced a response rate of 13% and a disease control rate (complete response/partial response/stable disease) of 46%. The current

study was designed by the GOG to test the therapeutic benefit of single-agent cetuximab in the setting of treatment failure with 1 or 2 prior regimens for metastatic cervical cancer with squamous and non-squamous histology. In this group of heavily pretreated patients cetuximab showed limited activity, with a response rate of 0% and 14.3% of patients remaining without progression after 6 months on protocol. Because the required number of patients with either responses or PFS at 6 months to declare the regimen interesting was 7 and 7 out of 35 patients (20.0%), respectively, the study was negative for the entire population. A median OS of 6.7 months was found in the current study. It is worth noting, however, that 5 out of 24 of the study patients (21%) who survived progression free for at least 6 months on cetuximab therapy harbored tumors with squamous cell histology. In contrast, no patient survived progression free for at least 6 months in the group of patients treated with cetuximab harboring adenosquamous or adenocarcinoma of the cervix (0 out of 11 patients). Consistent with these results, the point estimates for the probability of being PFS at 6 months when receiving cetuximab therapy was higher among the patients harboring squamous tumors than the whole sample (21% versus 14%). Thus, although the overall level of activity in the current report does not justify a phase III trial of cetuximab in heavily pretreated advanced and recurrent cervical cancer patients, current data cannot rule out potential activity of cetuximab in patients harboring cervical tumors with squamous cell histology.

The safety profile of cetuximab has been extensively studied in previous reports [37–41]. The present study did not identify any new toxicities or an increased frequency of currently reported toxicities of cetuximab in cervical cancer patients with persistent or recurrent disease. Most of the Grade 3 adverse events reported in the study were related to dermatologic toxicity.

In the current trial, patients were not prescreened or preselected on the basis of EGFR expression. It is worth noting, however, that the relation between EGFR protein expression and response to EGFR-target therapies is questionable, as colorectal cancer patients without detectable EGFR protein over-expression may respond to treatment with cetuximab [41]. Moreover, multiple previous studies have shown that EGFR is overexpressed in a large number of cervical cancers, and that it is significantly more expressed in squamous cell carcinoma than in adenocarcinoma and the upregulation is correlated with poor prognosis [42]. Of interest, multiple biomarkers have been found to predict response to treatment with EGFR inhibitors in other human malignancies. For example, in colorectal cancer and non–small cell lung cancer, KRAS mutations are associated with resistance to EGFR inhibitors, whereas specific EGFR mutations and high copy numbers of the EGFR gene predict a better response in non–small cell lung cancer [43–45]. In cervical cancer, however, neither EGFR mutations nor EGFR gene amplification and only a few (0–8%) KRAS mutations have been reported [46–51].

Although multiple mechanisms of action have been attributed to cetuximab including inhibition of tumor proliferation, angiogenesis and metastasis, induction of apoptosis, and/or promotion of cell cycle arrest, strong experimental evidence suggests that engagement of Fc receptors on effector cells (i.e., mainly natural killer (NK) cells) represents the dominant component of the *in vivo* activity of most antibodies against tumors [52–55]. The efficacy of the anti-EGFR antibody (M225) when used as an $F(ab)_2$ in blocking the growth of tumors *in vivo* has been previously demonstrated to be only 50% of the activity shown by the intact antibody when it is able to engage the Fc receptors on NK cells [53]. These findings suggest that host factors related to a low number and/or lack of killing activity of effector cells (i.e., NK cells), as previously reported by multiple groups studying the immune-competence of cervical cancer patients heavily pretreated with radiation and chemotherapy, may present a major barrier to the successful clinical development of therapeutic biologic reagents (i.e.,

IgG$_1$ mAb such as cetuximab) in end-stage cervical cancer patients [56–58]. Prospective evaluation of the immune-competence of such patients therefore seems to be warranted in future studies.

In conclusion, our study indicates that cetuximab has limited activity in patients with persistent or recurrent cervical cancer that has progressed after chemo-radiation and palliative chemotherapy. Cetuximab seems to be well tolerated in this patient population and its activity may be greater in patients with squamous cell histology.

Acknowledgments

REFERENCES

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010; 60:277–300. [PubMed: 20610543]

2. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350:535–40. [PubMed: 9284774]

3. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 2002; 29:3–9. [PubMed: 12422308]

4. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol. 2000; 18:54S–59S. [PubMed: 11060328]

5. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000; 60:15–23. discussion, 41–42. [PubMed: 11129168]

6. Baselga J. Targeting the epidermal growth factor receptor: A clinical reality. J Clin Oncol. 2001; 19:41S–44S. [PubMed: 11560970]

7. O'Dwyer PJ, Benson AB III. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol. 2002; 29(Suppl 14):10–1. [PubMed: 12422309]

8. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19:6550–65. [PubMed: 11426640]

9. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002; 110:669–72. [PubMed: 12297041]

10. Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signaling on the surface of living cells. Nat Cell Biol. 2000; 2:168–72. [PubMed: 10707088]

11. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000; 103:211–25. [PubMed: 11057895]

12. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem. 1999; 274:17209–18. [PubMed: 10358079]

13. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res. 1999; 253:78–87. [PubMed: 10579913]

14. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37(suppl 4):S9–S15. [PubMed: 11597399]

15. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst. 1997; 89:341–3. [PubMed: 9060954]

16. Corvo R, Antognoni P, Sanguineti G. Biological predictors of response to radiotherapy in head and neck cancer: Recent advances and emerging perspectives. Tumori. 2001; 87:355–63. [PubMed: 11989586]

17. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999; 5:577–86. [PubMed: 10100709]

18. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, et al. Synchronous co-expression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res. 2004; 10:1366–74. [PubMed: 14977838]

19. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18:904–4. [PubMed: 10673534]

20. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst. 1996; 88:1770–6. [PubMed: 8944008]

21. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA. 1983; 80:1337–41. [PubMed: 6298788]

22. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983; 1:511–29. [PubMed: 6094961]

23. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994; 269:27595–602. [PubMed: 7961676]

24. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 1996; 12:1397–403. [PubMed: 8622855]

25. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene. 1998; 17:999–1007. [PubMed: 9747879]

26. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997; 151:1523–30. [PubMed: 9403702]

27. Matsumoto T, Perrotte P, Bar-Eli M, et al. Blockade of EGF-R signalling with anti-EGFR monoclonal antibody (Mb) C225 inhibits matrix metalloproteinase-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo. Proc Am Assoc Cancer Res. 1998; 39:83. Abs.

28. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr. et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993; 85:1327–33. [PubMed: 8340945]

29. Milas L, Mason K, Hunter N, Petersen S, Yamakawwa M, Ang K, et al. In vivo enhancement of tumor radio response by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000; 6:701–8. [PubMed: 10690556]

30. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with

irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002; 8:994–1003. [PubMed: 12006511]

31. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22:1201–8. [PubMed: 14993230]

32. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001; 7:1204–13. [PubMed: 11350885]

33. Sill, MW.; Yothers, G. Technical Report. State University of New York at Buffalo; Buffalo: 2006. A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials.

34. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society Seriess B. 1972; 34:187–220.

35. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005; 7:419–34. [PubMed: 16221379]

36. Long HJ III, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol. 2005; 23:4626–33. [PubMed: 15911865]

37. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19:3234–43. [PubMed: 11432891]

38. Bonner J, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354:567–78. [PubMed: 16467544]

39. Baselga J, Trigo J, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol. 2002; 21:226a. Abstract 900.

40. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25:2171–7. [PubMed: 17538161]

41. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005; 23:1803–0. [PubMed: 15677699]

42. Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res. 2009; 15:7389–97. [PubMed: 19920104]

43. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008; 9:962–72. [PubMed: 18804418]

44. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007; 13:2890–6. [PubMed: 17504988]

45. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008; 26:3351–7. [PubMed: 18612151]

46. Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, et al. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer. 2008; 18:749–54. [PubMed: 17949425]

47. Marzano R, Corrado G, Merola R, Sbiroli C, Guadagni F, Vizza E, et al. Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression. Eur J Cancer. 2004; 40:1624–9. [PubMed: 15196550]

48. Stenzel A, Semczuk A, Rozynskal K, Jakowicki J, Wojcierowski J. "Low-risk" and "high-risk"HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases. Pathol Res Pract. 2001; 197:597–603. [PubMed: 11569923]

49. Pochylski T, Kwasniewska A. Absence of point mutation in codons 12 and 13 of K-RAS oncogenein HPV-associated high grade dysplasia and squamous cell cervical carcinoma. Eur J Obstet Gynecol Reprod Biol. 2003; 111:68–73. [PubMed: 14557015]

50. Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol. 2007; 105:662–6. [PubMed: 17360030]

51. Pappa KI, Choleza M, Markaki S, Giannikaki E, Kyroudi A, Vlachos G, et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol. 2006; 100:596–600. [PubMed: 16256179]

52. Farley JH, Oliver KE. Cisplatin plus Cetuximab in the Treatment of Recurrent and Persistent Cancers of the Cervix US Oncological Review. 2010; 6:45–49.

53. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993; 53:4322–8. [PubMed: 8364927]

54. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000; 6:443–6. [PubMed: 10742152]

55. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol. 2007; 106:513–20. [PubMed: 17540437]

56. Fiander A, Adams M, Evans AS, Bennett AJ, Borysiewicz LK. Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients. Int J Gynecol Oncol. 1995; 5:438–42.

57. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Rad Oncol Biol Phys. 2000; 48:997–1006.

58. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, et al. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. Int J Rad Oncol Biol Phys. 2002; 54:1345–55.

RESEARCH HIGHLIGHTS

- The GOG evaluated the efficacy and tolerability of Cetuximab in cervical cancer

- Cetuximab is well tolerated but has limited activity in persistent/recurrent disease

- Cetuximab activity may be limited to cervical cancer with squamous cell histology

Figure 1.
Kaplan-Meier estimates of PFS and OS for the entire study population.

Figure 2.
Kaplan-Meier estimates of PFS and OS for the study population of patients harboring squamous versus non-squamous cervical cancer.

Table 1

Patient Characteristics

Characteristic	Category	No. of	% of
Age	30–39	3	8.6
	40–49	16	45.7
	50–59	10	28.6
	60–69	6	17.1
Race	Asian	2	5.7
	African American	5	14.3
	Hispanic	2	5.7
	White	26	74.3
Performance Status	0	24	68.6
	1	9	25.7
	2	2	5.7
Cell Type	Adenocarcinoma, Unsp.	4	11.4
	Mixed Epithelial Carcinoma	1	2.9
	Adenosquamous	6	17.1
	Squamous Cell Carcinoma	24	68.6
Grade	1: Well differentiated	6	17.1
	2: Moderately differentiated	16	45.7
	3: Poorly differentiated	12	34.3
	Unknown	1	2.9
Prior Chemotherapy	1 Prior Regimen	25	71.4
	2 Prior Regimens	10	28.6
Prior Radiation	No	4	11.4
	Yes	31	88.6
Prior Surgery	No	19	54.3
	Yes	16	45.7

Table 2

Patient Response and Progression-Free Survival Status

Characteristic	Category	No.	% of
Response	Stable disease	11	31.4
	Increase disease	23	65.7
	Indeterminate	1	2.9
PFS > 6 Months	No	30	85.7
	Yes	5	14.3
Cycles of	1	7	20.0
	2	18	51.4
	3	1	2.9
	4	4	11.4
	6+	5	5.7
Alive	Without progression	1	2.9
	With progression	6	17.1
Dead	From disease	26	74.3
	From Rx and disease	1	2.9
	From neither Rx nor	1	2.9

The observed proportion responding was 0.0%. The approximate 90% confidence interval for the true response rate is 0 – 6.4%. The observed proportion of patients surviving progression free for at least 6 months was 14.3%. The approximate 2-sided 90% CI for the probability of being PFS at 6 months is 5.8 – 30.0%. The approximate 1-sided 90% CI for the probability of being PFS at 6 months is 0.0– 26.8%. The required number of patients with either responses or PFS at 6 months to declare the regimen interesting was 7 and 7 out of 35 patients (20.0%), respectively.

Table 3

Toxicity Table

AE Category	0	1	2	3	4	Total
Leukopenia	28	6	1	0	0	35
Thrombocytopenia	33	2	0	0	0	35
Neutropenia	33	1	1	0	0	35
Anemia	13	9	11	2	0	35
Other Hematologic	31	2	2	0	0	35
Allergy/Immunology	34	1	0	0	0	35
Constitutional	15	12	5	3	0	35
Dermatologic	8	9	13	5	0	35
Nausea	25	8	2	0	0	35
Vomiting	26	7	1	1	0	35
Gastrointestinal	19	9	3	4	0	35
Hemorrhage	34	1	0	0	0	35
Infection	31	0	2	2	0	35
Metabolic	22	8	4	1	0	35
Musculoskeletal	33	1	1	0	0	35
Neurological	33	1	0	1	0	35
Ocular/Visual	33	1	1	0	0	35
Pain	25	4	4	2	0	35
Pulmonary	30	4	0	1	0	35
Vascular	33	0	0	2	0	35

*
One patient death reported by an institution was listed as due to disease. The DSMB listed her death as due to disease and possibly treatment. She had grade 4 pain with hematuria.

Table 4

Cox Proportional Hazard Ratio Estimates for Various Prognostic Factors

Progression-Free Survival		
Prognostic Factor	**Hazard Ratio**	**95% Confidence Interval**
Performance Status[1]	1.77	0.82 – 3.82
Race[2]	0.69	N/A[4]
Squamous Histology[3]	0.72	0.33 – 1.52

Overall Survival		
Performance Status[1]	2.42	1.01 – 5.78
Race[2]	1.02	N/A[4]
Squamous Histology[3]	0.72	0.33 – 1.57

[1] Performance Status of 1 or 2 versus 0

[2] African American versus all other races

[3] Squamous Cell Type versus all other cell types

[4] The confidence interval could not be determined because there were only 5 African Americans.